Tirzepatide
Brand names: Mounjaro, Zepbound
Average weight loss
~22%
of body weight
What is Tirzepatide?
Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By targeting two incretin hormones simultaneously, it delivers enhanced metabolic effects compared to GLP-1-only medications.
In clinical trials, tirzepatide has shown the highest average weight loss of any FDA-approved anti-obesity medication, making it a groundbreaking option for patients who qualify.
Dual mechanism of action
GLP-1 activation
Reduces appetite, slows gastric emptying, and improves insulin secretion — the same pathway as semaglutide.
GIP activation
Enhances fat metabolism, improves energy expenditure, and provides additional appetite suppression through a complementary pathway.
Dosing schedule
Clinical results
In the SURMOUNT clinical trials:
- - Participants lost an average of 22.5% of body weight at the highest dose
- - 96% of participants achieved at least 5% weight loss
- - 63% achieved at least 20% weight loss at the 15mg dose
- - Significant improvements in A1C, blood pressure, and lipids